Badreddin Edris's most recent trade in Edgewise Therapeutics Inc was a trade of 66,477 Common Stock done at an average price of $1.9 . Disclosure was reported to the exchange on Jan. 21, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 21 Jan 2026 | 66,477 | 127,686 | - | 1.9 | 128,301 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 21 Jan 2026 | 66,477 | 19,820 | - | 29.4 | 1,957,083 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 66,477 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.64 per share. | 21 Jan 2026 | 17,236 | 50,746 | - | 0.6 | 11,031 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 21 Jan 2026 | 17,236 | 104,365 | - | 29.4 | 507,428 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 17,236 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 13,690 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.39 per share. | 21 Jan 2026 | 13,690 | 33,510 | - | 0.4 | 5,339 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 21 Jan 2026 | 13,690 | 121,601 | - | 29.4 | 403,034 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.93 per share. | 21 Jan 2026 | 10,463 | 61,209 | - | 1.9 | 20,194 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 21 Jan 2026 | 10,463 | 86,297 | - | 29.4 | 308,031 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 10,463 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.71 per share. | 21 Jan 2026 | 7,605 | 135,291 | - | 0.7 | 5,400 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Sale of securities on an exchange or to another person at price $ 29.44 per share. | 21 Jan 2026 | 7,605 | 96,760 | - | 29.4 | 223,891 | Common Stock |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2026 | 7,605 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 240,000 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 169,712 | 0 (0%) | 0% | - | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 149,470 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 120,000 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Edris Badreddin | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Edris Badreddin | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 78,960 | 0 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 33,778 | 0 | - | - | Performance Share Units | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 01 Jul 2025 | 3,868 | 0 | - | - | Stock Option (Right to Buy) | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Mar 2025 | 12,078 | 173,710 (0%) | 0% | 54.3 | 655,331 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Mar 2025 | 3,924 | 185,788 (0%) | 0% | 53.1 | 208,450 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Mar 2025 | 3,598 | 170,112 (0%) | 0% | 55.1 | 198,331 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Mar 2025 | 400 | 169,712 (0%) | 0% | 56.2 | 22,481 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 10 Feb 2025 | 30,000 | 189,712 (0%) | 0% | 53.1 | 1,593,795 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 10 Jan 2025 | 78,960 | 78,960 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 10 Jan 2025 | 27,023 | 219,712 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2025 | 6,934 | 202,666 (0%) | 0% | 38.2 | 264,809 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2025 | 5,561 | 197,105 (0%) | 0% | 38.2 | 212,375 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2025 | 4,416 | 192,689 (0%) | 0% | 38.9 | 171,606 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Dec 2024 | 11,966 | 217,634 (0%) | 0% | 41.8 | 499,942 | Common Stock | |
| SpringWorks Therapeutics Inc | Edris Badreddin | Chief Operating Officer | 03 Dec 2024 | 8,034 | 209,600 (0%) | 0% | 42.2 | 339,394 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Sep 2024 | 12,300 | 237,300 (0%) | 0% | 40.1 | 493,408 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Sep 2024 | 4,620 | 232,680 (0%) | 0% | 41.1 | 189,955 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Sep 2024 | 3,080 | 229,600 (0%) | 0% | 42.1 | 129,591 | Common Stock | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2024 | 20,594 | 20,594 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Jun 2024 | 11,772 | 257,828 (0%) | 0% | 39.4 | 463,834 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Jun 2024 | 4,192 | 253,636 (0%) | 0% | 40.6 | 170,287 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Jun 2024 | 3,651 | 249,985 (0%) | 0% | 41.4 | 151,066 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 03 Jun 2024 | 385 | 249,600 (0%) | 0% | 42.0 | 16,184 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2024 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2024 | 42,312 | 279,535 (0%) | 0% | 0 | Common Stock | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2024 | 5,466 | 269,600 (0%) | 0% | 41.5 | 227,003 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 04 Jan 2024 | 4,469 | 275,066 (0%) | 0% | 38.0 | 169,643 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 05 Jan 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 05 Jan 2023 | 105,000 | 105,000 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 05 Jan 2023 | 33,994 | 242,032 (0%) | 0% | - | Common Stock | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 05 Jan 2023 | 3,326 | 238,706 (0%) | 0% | 27.5 | 91,532 | Common Stock | |
| Edgewise Therapeutics Inc | Badreddin Edris | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2022 | 42,087 | 42,087 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 07 Jan 2022 | 1,852 | 325,813 (0%) | 0% | 56.1 | 103,823 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 07 Jan 2022 | 1,483 | 237,223 (0%) | 0% | 26.4 | 39,166 | Common Stock | |
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 06 Jan 2022 | 81,420 | 81,420 | - | - | Stock Option (Right to Buy) | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 06 Jan 2022 | 26,124 | 327,665 (0%) | 0% | - | Common Stock | ||
| SpringWorks Therapeutics Inc | Badreddin Edris | Chief Operating Officer | 01 Jul 2021 | 32,000 | 301,541 (0%) | 0% | 85.3 | 2,731,088 | Common Stock |